Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma (Nasdaq: ZBIO) announced that on July 15, 2026, its board compensation committee granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to newly hired employees.

Rhea-AI Summary

Zenas BioPharma (Nasdaq: ZBIO) announced that on July 15, 2026, its board compensation committee granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to newly hired employees. The awards comprise non-qualified stock options for 35,750 shares and 79,050 RSUs under the 2026 Inducement Plan.

The stock options have a 10-year term and an exercise price of $29.41, equal to the common stock closing price on the grant date. Options vest 25% after one year from each employee’s start date, then monthly over 36 months. RSUs vest in four equal annual installments on July 15 from 2027–2030, subject to continued service.

Positive

• Inducement awards to new hires: 35,750 stock options and 79,050 RSUs
• Stock option exercise price set at market close on grant date: $29.41

Negative

• Potential future share dilution from 114,800 combined options and RSUs

News Explained

Granted on July 15, 2026, the 35,750 options and 79,050 RSUs give newly hired employees claims tied to Zenas BioPharma common stock; because vesting runs over four years and depends on continued service, they create potential future dilution for existing holders rather than an immediate share issuance.

Argus Jul 20 session 7 alerts

+3.96% close to close 0.2x rel. volume Open Argus

Details

Market reaction after inducement equity grants: ZBIO +3.96% in the Jul 20 session

+3.0% Peak in 3 hr

$1.86B Market Cap

In the Jul 20 session, ZBIO gained 3.96%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.0% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

ZBIO insiders recorded Net Buying of 120,000 shares across three transactions in the past 90 days. T...

Analysis

ZBIO insiders recorded Net Buying of 120,000 shares across three transactions in the past 90 days. That platform context adds a separate ownership signal, while the active S-3ASR shelf remains a financing consideration for this equity-award announcement.

Key Figures

Stock options granted: 35,750 shares RSUs granted: 79,050 units Option term: 10 years +5 more

Stock options granted

35,750 shares

July 15, 2026 inducement grant

RSUs granted

79,050 units

July 15, 2026 inducement grant

Option term

10 years

Stock options

Exercise price

$29.41 per share

Equal to the closing price on the Grant Date

Option vesting period

4 years

Stock options

Initial option vesting

25%

On the one-year employment anniversary

Monthly vesting installments

36 equal installments

Remaining stock option vesting

RSU vesting dates

July 15, 2027; July 15, 2028; July 15, 2029; July 15, 2030

Four equal installments

Historical Context

5 past events · Latest: Jun 17

5 events

1. Jun 17

   Inducement grants

   24h Move

   +6.5%

   Employee options and RSUs were granted under Nasdaq inducement rules.

2. Jun 11

   Conference presentation

   24h Move

   +11.5%

   Management presentation was scheduled for the H.C. Wainwright summit.

3. Jun 02

   Phase 3 clinical data

   24h Move

   +1.6%

   INDIGO met its primary and key secondary endpoints with comparable safety.

4. May 28

   BLA submission

   24h Move

   +2.6%

   The company submitted an obexelimab biologics license application to the FDA.

5. May 19

   Phase 3 results

   24h Move

   +6.5%

   INDIGO reported reduced flare risk and favorable secondary endpoint results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 35,750 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"an aggregate of 79,050 restricted stock units of the Company's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 35,750 shares of the Company’s common stock (“Stock Options”) and an aggregate of 79,050 restricted stock units of the Company’s common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees’ entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).

The Stock Options have a ten-year term and an exercise price per share of $29.41, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Stock Options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of each of the employees’ first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments. The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of July 15, 2027, July 15, 2028, July 15, 2029 and July 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.

The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.

Investor and Media Contact:

Argot Partners
Zenas@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grants did Zenas BioPharma (NASDAQ: ZBIO) announce on July 17, 2026?

Zenas BioPharma announced inducement equity grants consisting of stock options and RSUs for new employees. According to Zenas BioPharma, these awards were approved on July 15, 2026 under its 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

How many stock options and RSUs were granted to new Zenas BioPharma (ZBIO) employees on July 15, 2026?

New Zenas BioPharma employees received options for 35,750 shares and 79,050 RSUs. According to Zenas BioPharma, these equity awards were granted as inducement grants in connection with their hiring and are subject to the terms of the company’s 2026 Inducement Plan and award agreements.

What are the vesting terms for Zenas BioPharma’s ZBIO inducement stock options granted on July 15, 2026?

The inducement stock options vest over four years. According to Zenas BioPharma, 25% vests on the one-year anniversary of each employee’s first employment day, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service with the company.

What are the vesting dates for Zenas BioPharma (ZBIO) inducement RSUs granted in 2026?

The inducement RSUs vest in four equal annual installments. According to Zenas BioPharma, 25% of the RSUs vest on each of July 15, 2027, 2028, 2029, and 2030, conditioned on the employee’s continued service through each applicable vesting date.

What is the exercise price and term of Zenas BioPharma’s ZBIO inducement stock options?

The inducement stock options have a ten-year term and a $29.41 exercise price. According to Zenas BioPharma, the exercise price equals the closing price of its common stock on the July 15, 2026 grant date, aligning awards with the market price that day.

How does Nasdaq Listing Rule 5635(c)(4) apply to Zenas BioPharma’s July 2026 inducement grants (ZBIO)?

Zenas BioPharma states that its July 15, 2026 inducement grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Zenas BioPharma, the stock options and RSUs were granted as a material inducement to the new employees’ entry into employment.